# Hydrocortisone 
## Introduction
* synthetic cortisol
    * cannot be bioanalytically separated from endogenous cortisol [[2018_Melin]](https://doi.org/10.1007/s40262-017-0575-8)
* the relatively short half-life of 1.5 h
* lack of licensed formulation for this population (for <6yo)
* Dose
    + still growing children: 8 mg/m$^2$/day divided in 3-4 doses [[2016_Bornstein]](https://doi.org/10.1210/jc.2015-1710)
    + more specific:  10-15 mg/m$^2$ · d divided into 3 doses [[2010_Speiser]](https://doi.org/10.1210/jc.2009-2631)
    + recommended daily dose to adult patients with adrenal insufficiency [[2016_Bornstein]](https://doi.org/10.1210/jc.2015-1710)
        + at 06:00 10 mg
        + at 14:00 5 mg
        + at 22:00 5 mg 
* modified release formulations [[2016_Porter]](https://doi.org/10.1136/archdischild-2015-309538)
    + Plenadren 
    + Chronocort
* administration 
    + subcutaneously via insulin -> circadian cortisol profile and improved 17-OHP concentrations [[2014_Hindmarsh]](https://doi.org/10.1111/cen.12453)
* BCS (biopharmaceutical classification system) **class II** [[1995_Amidon]](https://doi.org/10.1023/a:1016212804288)
    + low dissolution rate and high intestinal permeability [[2008_Lennernäs]](https://doi.org/10.1517/17425255.4.6.749)

---

## Pharmacokinetics
### Absorption
* Parameters
    + passive diffusion and is a poor substrate for the efflux protein P-glycoprotein [[2008_Lennernäs]](https://doi.org/10.1517/17425255.4.6.749)
    + $T_{max}$
        - tablet 1-1.7 h 
            - note: 1.7 h in high dose 50 mg [[TBA]]()
        - solution 0.7-1 h
        - pediatric adrenal insufficiency 0.33-3 h
    + $t_{1/2,abs}$ [[2004_Mah]](https://doi.org/10.1111/j.1365-2265.2004.02106.x)
        - fasting: 15 min
        - fed: 43 min 
    + $C_{max}$
        - 75th percentile of observed data [[1997_Knutsson]](https://doi.org/10.1210/jcem.82.2.3769)
    + F 
        - 100% when dose of <20 mg
        - 54% when dose of 50 mg in patients with adrenal insufficiency [[1984_Heazelwood]](https://doi.org/10.1111/j.1365-2125.1984.tb04999.x)
### Distribution
* Parameters
    + $V_{c}$
        - 7 to 23.9 L iv
        - 28.4 L when dose of 50 mg in patients with adrenal insufficiency [[1984_Heazelwood]](https://doi.org/10.1111/j.1365-2125.1984.tb04999.x)
    + $V_{c}/F$ or relative volume of distribution
        - 38.7-52.3 L patients with adrenal insufficiency
        - 17.5 ± 10.5 L pediatric patients [[2015_Sarafoglou]](https://doi.org/10.1097/jim.0000000000000121)
        - 27.1 ± 8.4 L prepubertal 
        - 49.5 ± 12.2 L pubertal
        - 40.8 ± 16.0 L prepubertal
            - [[2001a_Charmandari]](https://doi.org/10.1210/jcem.86.6.7522)
    + $V_{ss}$
        - increasing with increasing doses [[1981_Toothaker]](https://doi.org/10.1007/bf01062332)
        - 5 mg: 20.7 ± 7.3 L
        - 40 mg: 37.5 ± 5.8 L
### Metabolism
* [[2006_Hoshiro]](https://doi.org/10.1111/j.1365-2265.2005.02412.x)
    + 11β-hydroxysteroid dehydrogenase
        - bidirectional 
        - type 1 (11β-HSD1) to cortisol liver and adipose
            - undetectable $<3$ months
            - stabilized approx. at 12 months
        - type 2 (11-βHSD2) to cortisone in kidney
            - increased from 0-52 weeks,
    + 5α-reductase(cortisol) and 5β-reductase (cortisone)
        - unidirectional
            - low in newborns 
            - highest activity >3 months
            - declined <52 weeks 
            - similar 3.5-17.5 years 
    + 3α-hydroxysteroid
        - unidirectional
    + 6β-hydroxylase (CYP3A4)
        - unidirectional
        - approx. 1%

![Cortisol](./screenshots/cortisol_metabolic_pathways.png)

*Metabolic pathway of cortisol. Figures were adopted from [PhD thesis of Johanna Melin](https://refubium.fu-berlin.de/handle/fub188/23620).*

### Elimination      
* Parameters
    + $CL$
        - dose-dependent CL
        - lower in neonates (due to maturation of metabolic enzymes)
        - 12.5 to 20.2 L/h (iv 5-50 mg)
        - 12.5 L/h (iv 5 mg)
        - 17.6 L/h (iv 40 mg)
        - note: Saturation of CBG leads to $CL_u$ increasing disproportionally with respect to $CL_{tot}$.
        - CL ($CL_u$)  remains constant, since it is independent of $f_u$.
    + $CL/F$
        - 19.1 L/h (oral 10-20 mg: F≈1)
        - 27.3 L/h (50 mg)
        - 12.4-25.6 L/h (patients with adrenal insufficiency)
        - note: highest value in pubertal patients
    + $AUC$
        - nonlinear processes (e.g. saturable plasma protein binding or saturable absorption)

---

## Pharmacodynamics
* Effect
    + endogenous cortisol synthesis
    + T cell dynamics [[2003_Mager]](https://doi.org/10.1177/0091270003258651)
* correlation with **17-OHP** concentration 
    + 1 h post dose
    + delayed inhibitory effect with r=-0.302 [[2001a_Charmandari]](https://doi.org/10.1210/jcem.86.6.7522)
* no correlation between AUC for cortisol and 17-OHP [[2015_Sarafoglou]](https://doi.org/10.1097/jim.0000000000000121)

---

## Formulations and Administration 
### Infacort ®
* <u>Diurnal Ltd</u>
* oral (po)
* hydrocortisone granules with taste masking
* analysis in adults with a NCA by [[2015_Whitaker]](https://doi.org/10.1210/jc.2014-4060)
    * does not account for known nonlinearities of cortisol

### Licensed oral Hydrocortisone tablet
* <u>Auden Mackenzie Ltd</u>
* oral (po)

### Hydrocortisone Succinate
* intravenous (iv) bolus 
* HC administration

---

